VolitionRx (NYSE: VNRX)

Last close As at 20/04/2024


0.02 (3.87%)

Market capitalisation


VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

Latest Insights

View More

Healthcare | Update

VolitionRx — Snaring sepsis, with early NETs detection

Healthcare | edison tv

Volition Webinar: Unraveling the web of NETs in sepsis



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Nidhi Singh

Nidhi Singh


Arron Aatkar

Associate analyst

Key Management

  • Cameron Reynolds


  • Jake Micallef

    Chief Scientific Officer

  • Scott Powell

    Director of IR

  • Terig Hughes


Balance Sheet

Forecast net debt (US$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (29.2) (36.4) (61.9)
Relative (27.3) (39.3) (68.4)
52 week high/low US$2.0/US$0.6


VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These efforts, coupled with its CE mark in Europe, are a strong foundation in rapid and simplified sepsis detection that seeks to address the limitations and complexities of the current standard of care. Sepsis (immune-system triggered organ dysfunction) has a worrisome prevalence, affecting c 50 million per year with a mortality rate of c 20–25%, exceeding the combination of many leading cancers. Further, every hour of delayed treatment increases the chances of mortality of this preventable condition by c 8%. In this note we recap VolitionRx’s recent clinical updates, as we look forward to near-term improvements in early sepsis detection.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2018A 0.0 (17.9) (18.0) (57.37) N/A N/A
2019A 0.0 (16.1) (16.1) (41.09) N/A N/A
2020E 0.0 (17.2) (17.4) (42.61) N/A N/A
2021E 0.1 (18.6) (18.8) (44.46) N/A N/A

Further insights



Volition: Views from the sharp end



Healthcare Week 2023

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest





VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free